Floris Engelhardt, PhD
Floris Engelhardt is co-founder and CEO of Kano Therapeutics, a biotech startup spun out of Professor Mark Bathe’s BioNano Lab at MIT, where she worked as postdoctoral researcher after obtaining her Doctoral Degree in Biophysics from the Technical University of Munich (TUM). In 2021, she secured a two year founder fellowship from Activate Global to support her mission to build a company for therapeutic replacement genes. In May 2022, Kano Therapeutics closed its Pre-Seed led by a Boston-based fund (The Engine) and followed by a German fund (Amino Collective). Kano is actively piloting their products with multiple public pharma companies and aims to enable drug programs in cancer immunotherapies as well as gene therapies for monogenetic disorders.
Event: Deeptech Entrepreneurship (October 29)